Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CRESCENT BIOPHARMA, INC. (CBIO)

Crescent Biopharma Q2 net loss widens to $24.8 million; cash runway into 2028

Negative Impact 3 of 5 earnings Written later

Crescent Biopharma reported a net loss of $24.8 million for the quarter ended June 30, 2026, up from $21.8 million a year earlier, with no revenue in either period. Research and development expenses rose to $19.4 million from $12.1 million, while general and administrative expenses were $8.7 million versus $8.9 million. The company said a July 2026 public offering extends its expected cash runway into the second half of 2028.

Key points

  • Net loss was $24.8 million, or $0.74 per basic and diluted share, for Q2 2026, compared with $21.8 million, or $4.93 per share, for Q2 2025.
  • R&D expenses were $19.4 million versus $12.1 million a year earlier, driven by chemistry, manufacturing and controls costs and clinical activity.
  • Cash and cash equivalents were $171.6 million at June 30, 2026; pro forma cash was $305.1 million after $133.5 million in net offering proceeds.
  • Clinical readouts for CR-001 are anticipated beginning in the first quarter of 2027.

The filing

CompanyCRESCENT BIOPHARMA, INC. (CBIO)
Form8-K, current report
Filed with the SECJul 30, 2026, 7:36 AM ET
Accession number0001628280-26-050805

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.